Merck will continue to grow our pipeline with a focus on researching and developing first-in-class or best-in-class medicines and vaccines in targeted areas such as atherosclerosis and cardiovascular disease, bone and respiratory diseases, diabetes and obesity, infectious diseases and novel vaccines, neuroscience and oncology therapies.

The content on this page was last modified on September 15, 2009.

Merck & Co., Inc., Whitehouse Station, NJ, USA, and Schering-Plough Corporation, Kenilworth, NJ, USA, are now one company. We have combined our global operations under the name Merck & Co., Inc. We are working to update our corporate responsibility Web site to reflect our new, combined, global organization.